Dividend Assets Capital LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 36.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,054 shares of the biopharmaceutical company’s stock after selling 12,400 shares during the quarter. Dividend Assets Capital LLC’s holdings in Pfizer were worth $963,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of PFE. MERIAN GLOBAL INVESTORS UK Ltd boosted its stake in shares of Pfizer by 44.9% in the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 67,211 shares of the biopharmaceutical company’s stock worth $2,933,000 after acquiring an additional 20,836 shares during the period. Valmark Advisers Inc. boosted its stake in Pfizer by 8.9% during the fourth quarter. Valmark Advisers Inc. now owns 31,156 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 2,544 shares during the last quarter. Whitener Capital Management Inc. boosted its stake in Pfizer by 3.0% during the fourth quarter. Whitener Capital Management Inc. now owns 19,837 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 585 shares during the last quarter. Cornell Pochily Investment Advisors Inc. boosted its stake in Pfizer by 52.8% during the fourth quarter. Cornell Pochily Investment Advisors Inc. now owns 17,840 shares of the biopharmaceutical company’s stock valued at $778,000 after buying an additional 6,167 shares during the last quarter. Finally, Kovack Advisors Inc. boosted its stake in Pfizer by 2.2% during the fourth quarter. Kovack Advisors Inc. now owns 57,912 shares of the biopharmaceutical company’s stock valued at $2,528,000 after buying an additional 1,250 shares during the last quarter. Institutional investors own 71.83% of the company’s stock.
PFE traded down $0.11 on Friday, reaching $43.32. 37,058,693 shares of the stock were exchanged, compared to its average volume of 23,986,496. The firm’s 50-day moving average is $42.32. Pfizer Inc. has a fifty-two week low of $36.00 and a fifty-two week high of $46.47. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $239.02 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 2.49 and a beta of 0.65.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.32%. Pfizer’s payout ratio is currently 48.00%.
In other Pfizer news, major shareholder Pfizer Inc purchased 50,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $850,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of Pfizer stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the transaction, the insider now owns 80,094 shares of the company’s stock, valued at approximately $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
Several equities research analysts have recently issued reports on PFE shares. Credit Suisse Group reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Goldman Sachs Group reiterated a “buy” rating and issued a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. Bank of America increased their price target on Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, April 1st. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $46.00 price target on shares of Pfizer in a report on Monday, June 17th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Thirteen analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $46.22.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.